Beruflich Dokumente
Kultur Dokumente
Original Contribution
a r t i c l e i n f o a b s t r a c t
Article history: Objective: The antifibrinolytic agent tranexamic acid (TXA) has demonstrated clinical benefit in trauma patients
Received 20 August 2014 with severe bleeding, but its effectiveness in patients with traumatic brain injury (TBI) is unclear. We conducted a
Received in revised form 19 September 2014 systematic review to evaluate the following research question: In ED patients with or at risk of intracranial hem-
Accepted 19 September 2014 orrhage (ICH) secondary to TBI, does TXA compared to placebo improve patients' outcomes?
Methods: MEDLINE, EMBASE, CINAHL, and other databases were searched for randomized controlled trial (RCT)
or quasi-RCT studies that compared the effect of TXA to placebo on outcomes of TBI patients. The main outcomes
of interest included mortality, neurologic function, hematoma expansion, and adverse effects. We used “Grading
quality of evidence and strength of recommendations” to assess the quality of trials. Two authors independently
abstracted data using a data collection form. Results from studies were pooled when appropriate.
Results: Of 1030 references identified through the search, 2 high-quality RCTs met inclusion criteria. The effect of
TXA on mortality had a pooled relative risk of 0.64 (95% confidence interval [CI], 0.41-1.02); on unfavorable func-
tional status, a relative risk of 0.77 (95% CI, 0.59-1.02); and on ICH progression, a relative risk of 0.76 (95% CI, 0.58-
0.98). No serious adverse effects (such as thromboembolic events) associated with TXA group were reported in
the included trials.
Conclusion: Pooled results from the 2 RCTs demonstrated statistically significant reduction in ICH progression
with TXA and a nonstatistically significant improvement of clinical outcomes in ED patients with TBI. Further ev-
idence is required to support its routine use in patients with TBI.
© 2014 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ajem.2014.09.023
0735-6757/© 2014 Elsevier Inc. All rights reserved.
1504 S. Zehtabchi et al. / American Journal of Emergency Medicine 32 (2014) 1503–1509
literature search, trial selection, data abstraction, quality assessment of web site revealed an ongoing large multicen-
trials, and reporting the results. ter trial (CRASH-3) on the topic with esti-
The following inclusion/exclusion criteria were applied for selecting mated completion date of 2016 [15].
eligible trials: We also identified a new trial (not recruiting
yet) on www.clinicaltrials.gov website that is
Participants ED patients with or at risk of intracranial planning to test the impact of pre-hospital
hemorrhage (ICH) secondary to TBI. We administration of TXA on the clinical out-
considered any plausible definition for TBI comes of TBI patients (trial registraion #
and “at risk of ICH” used by original articles. NCT01990768).
Intervention Intervention consisted of TXA administra- Data extraction Data from the identified studies were ab-
tion at any dose, route, and time after TBI. stracted independently by 2 of the authors
Control Placebo administration. (SZ and SGA) using a standardized form.
Outcomes The primary outcome measures were (a) When more than 1 technique was used to
death due to any cause after TBI assessed measure an outcome, data on all measures
at the end of the follow-up period sched- used were extracted separately. For studies
uled by original studies (eg, inhospital, with incomplete quantitative information
30-day, 6-month, etc) and (b) neurologic available, attempts were made to obtain
outcomes measured by any criteria pro- data from the study authors.
posed by the original studies such as Glas- The dichotomous outcomes were reported
gow Outcome Score and discharge status. by percentages and 95% confidence intervals
The secondary outcomes included hemor- (CIs) and relative risks. Data reported as con-
rhage progression, transfusion requirement, tinuous variables (eg, size of hematoma)
the need for neurosurgical intervention, and were summarized as mean with SD or me-
adverse effects (such as thromboembolic dians with quartiles, whichever used in the
events) associated with the use of TXA. original studies.
We also considered additional radiologic Quality assessment We used “Grading quality of evidence and
outcomes such as development of new strength of recommendations” criteria to as-
hemorrhage, mass effect, and midline shift, sess the quality of the included trial and rate
if reported by the original studies. the level of evidence [16]. Two authors (SZ
Study designs Only randomized controlled trials (RCTs) or and DKN) independently assessed the
quasi-RCTs that compared the impact of
TXA compared to placebo on outcomes of
TBI patients were considered for inclusion.
Literature search Using a predesigned search strategy devel-
oped by an expert medical librarian (LF), da-
tabases including MEDLINE (1946 to March
2014), EMBASE (1980 to March 2014),
CINAHL (1981 to March 2014), and the
Cochrane Library were searched. Additional
databases searched included web of Science,
Google Scholar, and clinicaltrials.gov. The
authors also searched the proceedings of
emergency medicine, hematology, trauma,
neurology, and neurosurgery conferences
to look for relevant presented abstracts. In
addition, we reviewed the bibliographies of
pertinent articles for citations of eligible
studies not identified in the electronic data-
bases. Lastly, the experts in the field were
contacted to solicit information about possi-
ble ongoing, unpublished studies. The
MEDLINE and EMBASE search strategies
are presented in the Appendix A.
Two authors (SZ and SGA), working inde-
pendently, reviewed all references and ob-
tained the full text of potentially relevant
articles. Disagreements were resolved by
consensus. The search identified a total of
1030 citations from the databases. After
excluding nonrelevant articles based on
their titles and abstracts (Fig. 1), 19 full
text articles were reviewed. Two RCTs met
the eligibility criteria [13,14]. Searching the
gray literature identified no additional stud-
ies. However, contacting the experts and
searching the clinical trials registration Fig. 1. Flow diagram of study selection process for systematic review.
S. Zehtabchi et al. / American Journal of Emergency Medicine 32 (2014) 1503–1509 1505
Table 1
Characteristics of the included trials
CRASH-2 Institution: 10 hospitals in India and Colombia TXA 1 gram intravenously Matching Primary: Total hemorrhage growth from the first (before
Intracranial Population: 270 adult (≥16 years old) (IV) over 10 minutes Placebo randomization) to second CT scan (24-48 h later)
Bleeding Study, Inclusion criteria: CRASH-2 inclusion criteria (trauma followed by an IV infusion of Secondary: (1) Significant of hemorrhage growth
2011, [13] with significant hemorrhage [SBP b90 mm Hg or 1 gram over 8 hours defined as an increase by ≥25% of total hemorrhage in
heart rate N110 or both] or at risk for significant relation to its initial volume, (2) new ICH, (3) change in
hemorrhage, within 8 h of injury) plus TBI (GCS ≤14 subarachnoid hemorrhage grade, (4) mass effect, (5)
and a brain CT compatible with TBI) new focal cerebral ischemia, and (6) clinical outcomes
Exclusion criteria: pregnant women and patients for (death from any cause, dependency, and need for
whom a second brain CT was not possible neurosurgical intervention)
Clinical outcomes were measured upon discharge, at 28
d, or at death, whichever came first
CT outcomes were measured in 249 patients who had
first and second CT. Clinical outcomes were measured in
all patients (n = 270)
Yutthakasemsunt Institution: single-center study in Thailand TXA 1 g IV over 30 minutes Matching Primary: 1. Progression of ICH revealed by CT scan at
et al, 2013 [14] Population: 240 adult (N16 years old) followed by an IV infusion of placebo 24 h (defined as new ICH on second CT, expansion of
Inclusion criteria: nonpenetrating TBI (GCS score 4- 1 g over 8 h existing ICH by 25% or more); 2. increase in pressure
12) within 8 h of onset and with no indication for effect (increase in midline shift of greater than 1 mm or
emergency neurosurgical intervention increase in basal cistern between first and second CT)
Exclusion criteria: patients with coagulopathy and an Secondary: Inhospital mortality, Glasgow Outcome Scale
elevated serum creatinine (N2 mg/dL) at hospital discharge, blood transfusion requirement,
neurosurgical intervention, and any inhospital
thromboembolic events
quality of the included trials. Their agree- Statistical heterogeneity was examined using the χ 2 and I 2 tests
ment on the assessment criteria was mea- for heterogeneity. Data were analyzed using STATA 11.0 statistical
sured by κ. software (STAT Corp, College Station, TX) with weighting for size of
Quantitative data synthesis The effect of TXA on dichotomous outcomes the trial.
was assessed using a random effects model
because the trials were expected to be
heterogeneous in their design and patient 3. Results
populations. Relative risk and 95% CIs were
calculated. We quantitatively synthesized 3 Two RCTs met the inclusion criteria [13,14]. The characteristics of the
outcome measures from the 2 randomized included trials are listed in Table 1.
trials—inhospital mortality, unfavorable Both studies were of high quality. κ representing the agreement of
functional status, and significant hemorrhage the 2 authors on elements of quality assessment was 1.0. The details
growth. The definitions of significant ICH and of the quality assessment of the 2 trials are listed in Table 2.
inhospital mortality differed slightly between The results of the included trials are summarized in Table 3. CRASH-
the 2 trials [13,14]. Because both trials used 2 Intracranial Bleeding Study (ICB) [13] also adjusted the outcomes by
slightly different measures of functional sta- Glasgow Coma Scale (GCS) score, age, time from injury to first comput-
tus at hospital discharge, we defined the out- ed tomography (CT), time from injury to second CT, and initial hemor-
come of unfavorable functional status as rhage volume. The results of the adjusted outcome analysis are
death, vegetative statue, fully dependent re- presented in Table 4.
quiring constant attention, or dependent The forest plots representing the pooled analysis of data pertaining
but not requiring constant attention. to the main outcomes are shown in Fig. 2.
Table 2
Quality assessment of the included trials
Randomization Yes, patient randomization was balanced by center Yes, computer randomization with random block size.
and with an allocation sequence based on a block size
of 8, generated with a computer random number
generator.
Concealment Yes, allocations were masked. Both randomization and Yes, group assignments were kept in opaque sealed
allocation assignments were kept in a different city by envelopes.
an international coordinating center. The study drug
and the placebo ampoules were indistinguishable.
Intention-to-treat analysis Yes Yes
Blinding Yes, double blinded (subjects and investigators). Yes, subjects, caregivers, and outcome assessors
were blinded.
Follow-up 270/270 (100%) with clinical follow-up 227/238 (95.4%) had primary outcome analyzed
249/270 (92.2%) for CT outcomes (21 missed: 10 in (11 missed [5 in treatment group and 6 in placebo]: 2
treatment group and 11 in placebo group) inappropriate consent, 7 dead, 1 agitated, 1 refused)
Outcome reporting bias None identified None identified
Quality of evidence High High
1506 S. Zehtabchi et al. / American Journal of Emergency Medicine 32 (2014) 1503–1509
Table 3
Summary of the reported outcomes by the included trials comparing TXA to placebo in ED patients with TBI
Study Outcomes TXA, n/N; % (95% CI) Placebo, n/N; % (95% CI) Relative risk (95% CI)
CRASH-2 ICB Study, 2011 [13] Total hemorrhage growth (mean ± SD) a 5.9 mL (±27) 8.1 mL (±29) b
Significant hemorrhage growth c 44/123; 36% (28%-45%) 56/126; 44% (36%-53%) 0.80 (0.59-1.09)
Area of new hemorrhage on repeat CT (not seen on initial CT) 13/123; 11% (6%-17%) 20/126; 16% (11%-23%) 0.66 (0.35-1.28)
d
Change in subarachnoid hemorrhage grade −0.11 −0.12
Presence of mass effect on CT 58/123; 47% (39%-56%) 76/126; 60% (52%-68%) 0.78 (0.06-0.99)
New focal cerebral ischemia 6/123; 5% (2%-10%) 12/126; 10% (6%-16%) 0.51 (0.19-1.32)
Mortality at discharge or 28 d (whichever came first) 14/133; 11% (6%-17%) 24/137; 18% (12%-26%) 0.60 (0.33-1.11)
Dependency in survivors e 26/119; 22% (15%-30%) 29/113; 26% (19%-34%) 0.85 (0.54-1.35)
Need for neurosurgical intervention at discharge or 28 d 20/133; 15% (10%-22%) 21/137; 15% (10%-22%) 0.98 (0.56-1.72)
Composite outcome f 60/133 45% (36%-54%) 80/137; 58% (50%-67%) 0.77 (0.61-0.98)
Yutthakasemsunt et al, 2013 [14] Significant hemorrhage growth g 21/120; 18% (12%-25%) 32/118; 27% (20%-36%) 0.65 (0.39-1.05)
Increase in intracranial pressure effect h 11/114; 10% (5%-16%) 12/115; 11% (6%-17%) 0.92 (0.60-1.40)
Improved GCS motor score at 24 h 37/120; 31% (23%-40%) 37/118; 31% (23%-41%) 0.98 (0.67-1.40)
Inhospital mortality 12/120; 10% (6%-17%) 17/118; 14% (9%-22%) 0.69 (0.35-1.39)
Unfavorable Glasgow Outcome Scale at hospital discharge i 21/120; 18% (12%-25%) 27/118; 23% (16%-31%) 0.76 (0.46-1.27)
Blood transfusion requirement 31/120; 26% (19%-34%) 33/118; 28% (21%-37%) 0.92 (0.60-1.40)
Need for neurosurgic intervention 3/120; 3% (1%-7%) 0/118; 0% (0%-3%) j 5.95 (0.30-117)
Inhospital thromboembolic events 0/120; 0% (0%-3%) j 4/118; 3% (1%-8%) 0.12 (0.01-2.28)
a
Defined as change in total volume from all hemorrhagic lesions between initial and repeat CT (at 24-48 hours).
b
Unadjusted: reduction of −2.1 mL, 95% CI −9.8 to 5.6; adjusted: reduction of −3.8 mL, 95% CI, −11.5 to 3.9, P = 0.33.
c
Defined as greater than or equal to 25% increase in total volume from all hemorrhagic lesions between initial and repeat CT (at 24-48 hours).
d
P = 0.93.
e
Measured using the 5-point modified Oxford Handicap Score and dichotomized into dependent (fully dependent required attention day and night or dependent not requiring constant
attention) or independent (some restriction in lifestyle but independent, minor symptoms, or no symptoms).
f
Significant hemorrhage growth, area of new hemorrhage, new focal cerebral ischemic lesion, need for neurosurgical intervention, and death.
g
Defined as greater than or equal to 25% increase of ICH in any dimension (height, length, or width) or new ICH between initial and repeat CT (at 24 ± 8 hours).
h
Defined as increase in midline shift of greater than 1 mm or an increase in basal cistern between the first and second CT scan.
i
Defined as death, persistent vegetative state, and severe disability.
j
0.5 added to both cells to obtain CIs.
No adverse events related to TXA was reported in CRASH-2 ICB [13]. 4. Discussion
In the study by Yutthakasemsunt et al [14], 4 cases of inhospital throm-
boembolic events were documented in the placebo group, but none was Improving the outcome of brain injury patients largely depends on
reported in the TXA group. minimizing the secondary brain insults because the extent of primary
We were not able to examine the impact of TXA on outcome of TBI brain damage after TBI cannot be modified. Secondary insults include
patients with isolated head injury alone. In the study of hematoma expansion, cerebral edema, increased intracerebral pressure,
Yutthakasemusunt et al [14], 17% (n = 20) and 14% (n = 16) of pa- infection, hypoxia, and coagulopathy. The brain tissue contains large
tients in TXA and placebo groups had isolated head injury, respec- amounts of thromboplastin. This substance is released in high concen-
tively. The authors did not evaluate the outcomes in this subgroup tration into the blood stream after physical trauma to the parenchyma,
because of the small sample size. Similarly, the CRASH-2 ICB [13] au- causing disturbance in coagulation processes [17,18]. In addition, dam-
thors also indicated that only a small number of patients in their aged cerebral endothelium activates platelets as well as clotting cas-
study had isolated head injury and the outcomes could not be cades to produce intravascular thrombosis and depletion of
assessed in this particular subgroup. coagulation factors [19,20].
Table 4
The adjusted analysis of the reported outcomes in the CRASH-2 Intracranial Bleeding Study, comparing TXA to placebo in ED patients with TBI
Study Outcomes TXA, n/N; % (95% CI) Placebo, n/N; % (95% CI) Adjusted odds ratio a (95%CI)
b c
CRASH-2 ICB Study, 2011 [13] Total hemorrhage growth (mean ± SD) 5.9 mL (±27) 8.1 mL (±29)
Significant hemorrhage growthd 44/123; 36% (28%-45%) 56/126; 44% (36%-53%) 0.67 (0.40-1.13)
Area of new hemorrhage on repeat CT 13/123; 11% (6%-17%) 20/126; 16% (11%-23%) 0.62 (0.28-1.35)
(not seen on initial CT)
Presence of mass effect on CT 58/123; 47% (39%-56%) 76/126; 60% (52%-68%) 0.59 (0.35-0.97) e
New focal cerebral ischemia 6/123; 5% (2%-10%) 12/126; 10% (6%-16%) 0.49 (0.18-1.44)
Mortality at discharge or 28 d 14/133; 11% (6%-17%) 24/137; 18% (12%-26%) 0.47 (0.21-1.04)
(whichever came first)
Dependency in survivorsf 26/119; 22% (15%-30%) 29/113; 26% (19%-34%) 0.66 (0.32-1.36)
Need for neurosurgical intervention at 20/133; 15% (10%-22%) 21/137; 15% (10%-22%) 0.98 (0.45-1.93)
discharge or 28 d
Composite outcomeg 60/133 45% (36%-54%) 80/137; 58% (50%-67%) 0.57 (0.33-0.98)
a
Adjusted by GCS score, time from injury to first CT, time from injury to second CT, and initial hemorrhage volume.
b
Defined as change in total volume from all hemorrhagic lesions between initial and repeat CT (at 24-48 hours).
c
Reduction of −3.8 mL, 95% CI, −11.5 to 3.9, P = .33.
d
Defined as greater than or equal to 25% increase in total volume from all hemorrhagic lesions between initial and repeat CT (at 24-48 hours).
e
Adjusted by GCS score, time from injury to first CT, time from injury to second CT, initial hemorrhage volume, and initial mass effect.
f
Measured using the 5-point modified Oxford Handicap Score and dichotomized into dependent (fully dependent required attention day and night or dependent not requiring constant
attention) or independent (some restriction in lifestyle but independent, minor symptoms, or no symptoms).
g
Significant hemorrhage growth, area of new hemorrhage, new focal cerebral ischemic lesion, need for neurosurgical intervention, and death.
S. Zehtabchi et al. / American Journal of Emergency Medicine 32 (2014) 1503–1509 1507
a - defined as death, vegetative state, or fully dependent requiring attention day and night
or dependent but not requiring constant attention
b - defined as ≥ 25% increase in total volume from all hemorrhagic lesions between initial and
repeat CT (at 24-48 hours)
Abbreviations: RR, relative risk; CI, confidence intervals; df, degrees of freedom
Fig. 2. Forest plots representing the effect of TXA on outcome of patients with TBI. A, Inhospital mortality. B, Unfavorable functional status at hospital discharge. C, Progression of hemorrhage.
1508 S. Zehtabchi et al. / American Journal of Emergency Medicine 32 (2014) 1503–1509
Tranexamic acid, a lysine analog, functions by inhibiting plasminogen younger than 38 years and, therefore, a population less frequently treat-
activation. This action allows mature fibrin clots to be maintained and ed with antiplatelet and anticoagulant therapy [13,14].
coagulation to continue uninhibited. The use of TXA for TBI to improve Although the study by Yutthakasemsunt et al [14] only enrolled
clinical outcomes is based on the theory that TXA may limit secondary nonpenetrating TBI, the CRASH-2 ICB [13] did not categorize TBI into
brain injury through 2 mechanisms. First, TXA, as an antifibrinolytic blunt or penetrating. The mechanism of injury could be a confounder
agent, may limit fibrinolysis and thus ICH progression. Fibrinolysis is that needs to be examined in future trials.
common in TBI and has been shown to be a strong independent predictor Lastly, the meta-analysis was performed with only 2 trials. Although
of ICH progression [21]. Second, TXA may inhibit the effect of tissue this fact limits the generalizability of the findings, the high quality of the
plasminogen activator, which plays a role in perilesional edema [22]. included trials and absence of significant heterogeneity validate
We identified 2 high-quality clinical trials that tested the hypothesis the analysis.
that administration of TXA to patients with TBI would reduce hematoma
growth compared with placebo [13,14]. Both trials were powered to de-
tect a difference in ICH progression (initial and repeat head CTs) but also 6. Conclusion
evaluated clinical outcomes as secondary outcome measures [13,14].
Although not statistically significant, both trials did demonstrate a Pooled results from the 2 RCTs demonstrated statistically significant
trend toward decreased ICH progression in the TXA cohort compared reduction in ICH progression with TXA and a nonstatistically significant
with placebo [13,14]. This trend was noted in a number of different improvement of clinical outcomes in ED patients with TBI. Despite an
measures of ICH progression including total volumetric growth, propor- excellent safety profile, further evidence is required to support the rou-
tion with significant (25%) hemorrhage growth, new area of hemor- tine use of TXA in patients with TBI. An ongoing, international, multi-
rhage, and the presence of mass effect. Both trials also demonstrated a center, phase III trial (CRASH-3) [15] evaluating the use of TXA on
slight trend (nonstatistically significant) toward improved mortality in death and disability in patients with TBI with a planned enrollment of
the TXA cohort [13,14]. 10000 patients will certainly shed light on this particular question.
After pooling the data pertaining to the 3 outcomes of inhospital mor-
tality, functional status, and hemorrhage progression, the meta-analysis
Conflict of interest
revealed a statistically significant reduction in hemorrhage progression
in TBI patients receiving TXA. The pooled relative risks for inhospital
SZ, LF, and DKN have no conflict of interest to report. SGA owns stock
mortality and functional status were not statistically significant.
options in Bio-Signal Group Corporation and is a coinventor on US pat-
The results of these 2 trials suggesting a trend toward decreased ICH
ents pending 61/554, 743 and 13/284, and 886. He is also the principal
progression with early administration of TXA should be viewed with
investigator of a National Institutes of Health–funded trial
caution. Hematoma expansion has been associated with poor outcome
5R41HD072881-02.
in patients with TBI [23]. Although this outcome likely lies on the causal
pathway to clinical outcomes such as functional status and mortality,
surrogate outcomes do not always translate into actual clinical outcomes Appendix A
[24]. For example, although an initial phase II clinical trial demonstrated
reduction in the hematoma growth and mortality after administration of Search strategy for MEDLINE and EMBASE
activated factor VII to patients with nontraumatic ICH [25], subsequent
Ovid MEDLINE (1946 to March 1, 2014)
phase III trial confirmed the reduction in hematoma growth but failed
to show improved survival or functional outcomes [26]. 1 exp Brain Injuries/ (48229)
2 Craniocerebral Trauma/ (18742)
3 (traumatic brain adj (injur$ or concussion$ or contusion$ or laceration$)).tw.
5. Limitations (16260)
4 (traumatic cerebral adj (injur$ or concussion$ or contusion$ or laceration$)).tw. (41)
Some limitations exist in the current body of evidence. We did not 5 (tbi or tbis).tw. (11582)
6 exp Intracranial Hemorrhages/ (54594)
identify any studies that were adequately powered to detect any clinical
7 ((brain or basal ganglia or cerebral or cranial or intracranial or posterior fossa or
outcomes. There was some heterogeneity between identified studies, Subarachnoid) adj2 (bleed$ or h?emorrhag$)).tw. (29410)
particularly in the inclusion criteria. The CRASH-2 Intracranial Bleeding 8 Pituitary Apoplexy.tw. (738)
Study [13] enrolled a broader range of TBI, with 45% having mild TBI 9 or/1-8 (127629)
(GCS score, 13-15), compared to Yutthakasemsunt et al [14], which en- 10 Antifibrinolytic Agents/ (3910)
11 Tranexamic Acid/ (1882)
rolled patients with moderate to severe TBI (GCS score, 4-12). Almost all
12 txa.tw. (833)
patients in the CRASH-2 Intracranial Bleeding Study [13] had significant 13 amca.tw. (229)
extracranial injuries. Because TXA has proven mortality benefit in pa- 14 amcha.tw. (113)
tients with significant hemorrhage [9], the trend toward improved mor- 15 amchafibrin.tw. (0)
16 amikapron.tw. (1)
tality in this study may be a result of limiting extracranial hemorrhage
17 amstat.tw. (0)
progression by TXA, and the benefits might not be the same in patients 18 anexan.tw. (0)
with isolated TBI. CRASH-2 ICB [13] study also had a protocol deviation 19 antivoff.tw. (0)
leading to enrollment of 31 patients (11%) with a GCS score of 15 and 7 20 caprilon.tw. (0)
patients (3%) with a normal initial head CT. Tranexamic acid would un- 21 (cl 65336 or cl65336).tw. (0)
22 cy?lo?apron.tw. (46)
likely have any clinical benefit in these patients. This issue could have
23 exacyl.tw. (5)
diluted the results of study. 24 fibrinon.tw. (0)
Neither trial was able to examine the outcomes in patients with iso- 25 frenolyse.tw. (1)
lated head injury due to the small number of such patients in both trials. 26 hemostan.tw. (0)
27 hexa?apron.tw. (0)
Therefore, it is difficult to distinguish the effects of TXA in TBI from that
28 kabi 2161.tw. (2)
of polytrauma. 29 kalnex.tw. (0)
The included studies did not account for patients receiving anticoag- 30 lysteda.tw. (6)
ulants or antiplatelet agents. Such therapies can significantly increase 31 micranex.tw. (0)
hemorrhage progression post TBI and thus interfere with TXA effects. 32 rikaparin.tw. (0)
33 ronex.tw. (0)
However, the mean age of the patients recruited in both studies was
S. Zehtabchi et al. / American Journal of Emergency Medicine 32 (2014) 1503–1509 1509